Before Ozempic, Wegovy, Mounjaro and Zepbound, there was Lotte Bjerre Knudsen. In the 1990s, the young scientist at the Danish drug company Novo Nordisk was trying to unlock the key to a new technology for treating Type 2 diabetes. To her bosses, Lotte’s project, which focused on a hormone called GLP-1, looked like a distraction. But as Lotte fought to save her diabetes project from the chopping block, she couldn’t have imagined how much of an impact her breakthrough would have. Her work would pave the way for a hit drug called Ozempic. And it would unleash a new class of blockbuster drugs, pitting two companies in a race to become the world’s first trillion-dollar pharmaceutical company by market cap. Listen to Part 1 of “Trillion Dollar Shot” now. Learn more about your ad choices. Visit megaphone.fm/adchoices
No persons identified in this episode.
This episode hasn't been transcribed yet
Help us prioritize this episode for transcription by upvoting it.
Popular episodes get transcribed faster
Other episodes from The Journal.
Transcribed and ready to explore now
Medicare, Inc. Part 1: How Insurers Make Billions From Medicare
06 Jun 2025
The Journal.
Deportations Could Upend This Parachute Factory
05 Jun 2025
The Journal.
The Struggle to Get Aid Into Gaza
04 Jun 2025
The Journal.
The Everyday American Who Hustled for North Korea
03 Jun 2025
The Journal.
Stop Making Cents: The End of the Penny
02 Jun 2025
The Journal.
Ron Howard and Brian Grazer on Longevity in Hollywood
01 Jun 2025
The Journal.